Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Altimmune Stock Performance

NASDAQ ALT opened at $4.46 on Thursday. The company’s 50 day simple moving average is $4.56 and its two-hundred day simple moving average is $4.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18. Altimmune has a 1 year low of $2.90 and a 1 year high of $7.73. The stock has a market capitalization of $503.22 million, a PE ratio of -4.17 and a beta of 0.09.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Citizens Jmp reduced their target price on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Barclays assumed coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $17.60.

Insiders Place Their Bets

In related news, Director John Gill acquired 12,500 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the acquisition, the director owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jerome Benedict Durso bought 12,500 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the purchase, the director directly owned 12,500 shares in the company, valued at approximately $51,625. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 30,527 shares of company stock valued at $125,278 in the last ninety days. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Northeast Financial Group Inc. bought a new stake in Altimmune in the 4th quarter worth about $48,000. &PARTNERS bought a new stake in shares of Altimmune during the 4th quarter valued at $54,000. Vontobel Holding Ltd. bought a new stake in Altimmune during the fourth quarter valued at about $54,000. Martingale Asset Management L P purchased a new stake in shares of Altimmune in the fourth quarter worth $52,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Altimmune during the fourth quarter worth about $44,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.